Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.

Dimitrios PatouliasChristodoulos PapadopoulosGeorge KassimisNikolaos FragakisVassilios VassilikosAsterios KaragiannisMichael Doumas

Published in: Vascular medicine (London, England) (2022)

SGLT-2 inhibitors do not decrease PWV in patients with established cardiovascular disease or cardiovascular risk factors. However, we have shown that SGLT-2 inhibitors lead to a slight, but significant decrease in PWV in patients with T2DM. The latter finding is of great value, based on the significant correlation between PWV and micro- and macro-vascular complications of T2DM.

Keyphrases

cardiovascular risk factors
cardiovascular disease
metabolic syndrome
type diabetes
blood pressure
risk factors
glycemic control
coronary artery disease
insulin resistance
weight loss